Journal
CANCER SCIENCE
Volume 100, Issue 12, Pages 2268-2274Publisher
WILEY
DOI: 10.1111/j.1349-7006.2009.01310.x
Keywords
-
Categories
Funding
- National Institute of Biomedical Innovation of Japan
- Third-Term Comprehensive Control Research for Cancer and Research on Biological Markers for New Drug Development
- Ministry of Health, Labor and Welfare of Japan
- Foundation for Promotion of Cancer Research (Tokyo, Japan).
Ask authors/readers for more resources
Osteosarcoma (OS) is the most frequent primary malignant bone tumor of children and young adults. Although the introduction of combined neoadjuvant chemotherapy has markedly improved survival, the outcome of OS patients with distant metastasis and/or poor response to chemotherapy is still unsatisfactory. Therefore there is a need to develop new therapeutic agents that suppress OS cell proliferation with higher efficacy. The protein kinases are a family of genes that play critical roles in various signaling pathways. Some cancer cells show addiction to constitutive activation of certain signaling pathways for proliferation and survival. To identify new drug targets for OS, we screened a panel of small interfering RNAs (siRNAs) that target 691 genes encoding human protein kinases and related proteins. We found that different constructs of siRNA specifically targeting polo-like 1 kinase (PLK1) significantly caused mitotic cell cycle arrest and subsequent apoptotic cell death in a variety of OS cell lines. siRNA targeting PLK1 also suppressed the growth of OS xenografts established in immunodeficient mice. Recently, phase I clinical trials of PLK1 chemical inhibitors have been reported. Our results indicate that PLK1 is a promising molecular target for pharmacologic intervention in OS. (Cancer Sci 2009; 100: 2268-2274).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available